Drug intelligence / Profile preview

tetanus toxoid helper peptide

Development stage
Approved
Lead developer
University of Virginia
Modality
Peptides, Vaccines & Immunotherapeutics
Administration
Subcutaneous, Intramuscular, Intradermal
01

Overview

Tetanus toxoid helper peptide is a synthetic peptide derived from the tetanus toxin protein sequence (commonly residues 830–843). It functions as a universal human T cell epitope and is widely used as an immunological adjuvant in vaccine formulations. Its primary mechanism is to induce robust CD4+ helper T cell responses by binding to class II MHC molecules, thereby enhancing the immune response to co-administered antigens. This property makes it valuable in cancer vaccines and other therapeutic vaccines where strong cellular immunity is desired. The peptide itself does not confer protection against tetanus but serves as an immunopotentiator for other vaccine components[2][4][6][8][9].

Other names
tetanus toxoid T-helper peptidetetanus toxin (830-843)T-helper epitope from tetanus toxoid
02

Targets

MHC II (Major histocompatibility complex class II receptor)

Beyond the preview

Go deeper on tetanus toxoid helper peptide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on tetanus toxoid helper peptide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call